The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Ribonucleotide Reductase Inhibitors and Future Drug Design
Abstract
Ribonucleotide reductase (RR) is a multisubunit enzyme responsible for the reduction of ribonucleotides to their corresponding deoxyribonucleotides, which are building blocks for DNA replication and repair. The key role of RR in DNA synthesis and cell growth control has made it an important target for anticancer therapy. Increased RR activity has been associated with malignant transformation and tumor cell growth. Efforts for new RR inhibitors have been made in basic and translational research. In recent years, several RR inhibitors, including Triapine, Gemcitabine, and GTI-2040, have entered clinical trial or application. Furthermore, the discovery of p53R2, a p53-inducible form of the small subunit of RR, raises the interest to develop subunit-specific RR inhibitors for cancer treatment. This review compiles recent studies on (1) the structure, function, and regulation of two forms of RR; (2) the role in tumorigenesis of RR and the effect of RR inhibition in cancer treatment; (3) the classification, mechanisms of action, antitumor activity, and clinical trial and application of new RR inhibitors that have been used in clinical cancer chemotherapy or are being evaluated in clinical trials; (4) novel approaches for future RR inhibitor discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Inayat, M. S., Damodaran, C., Mohiuddin, M., Elford, H. L., Gallicchio, V. S., & Ahmed, M. M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.174 · Cited by 100
RetractedDuxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Surgery · doi:10.1016/j.surg.2004.04.029 · Cited by 52
RetractedGewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Protein Radicals in Enzyme Catalysis
Stubbe, J., & van der Donk, W. A. (1998) · Chemical Reviews · doi:10.1021/cr9400875 · Cited by 1,377
Thelander, L., & Reichard, P. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,167
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876
Three-dimensional structure of the free radical protein of ribonucleotide reductase
Nordlund, P., Sjöberg, B.-M., & Eklund, H. (1990) · Nature · doi:10.1038/345593a0 · Cited by 835
Stubbe, J., Nocera, D. G., Yee, C. S., & Chang, M. C. Y. (2003) · Chemical Reviews · doi:10.1021/cr020421u · Cited by 823
INTERACTIONS BETWEEN DEOXYRIBONUCLEOTIDE AND DNA SYNTHESIS
Reichard, P. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.002025 · Cited by 779
Cited by
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015) · Oncogene · doi:10.1038/onc.2014.155 · Cited by 436
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Self-citationD'Angiolella, V., Donato, V., Forrester, F. M., Jeong, Y.-T., Pellacani, C., Kudo, Y., Saraf, A., Florens, L., Washburn, M. P., & Pagano, M. (2012) · Cell · doi:10.1016/j.cell.2012.03.043 · Cited by 395
Metadata
- Authors
- Shao, J., Zhou, B., Chu, B., & Yen, Y.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-08-01
- Volume
- 6
- Issue
- 5
- Pages
- 409-431
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2103041841
- Cited by
- 284
- References
- 199
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ribonucleotide Reductase Inhibitors and Future Drug Design. https://app.cochat.ai/papers/10.2174/156800906777723949
- The paper
- Shao, J., Zhou, B., Chu, B., & Yen, Y. (2006). Ribonucleotide Reductase Inhibitors and Future Drug Design. Current Cancer Drug Targets. https://doi.org/10.2174/156800906777723949
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.